nach oben

Erschienen in:

18.07.2020 | Original Article

Determinant factors of sarcopenia in individuals with Parkinson’s disease

verfasst von: Marcella Campos Lima da Luz, Gleyce Kelly Araújo Bezerra, Amdore Guescel C. Asano, Maria da Conceição Chaves de Lemos, Poliana Coelho Cabral

Erschienen in: Neurological Sciences | Ausgabe 3/2021

Einloggen, um Zugang zu erhalten

Abstract

Objective

Evaluate the occurrence of sarcopenia and determinant factors in individuals with Parkinson’s disease (PD) in a city in northeastern Brazil.

Methods

Case series with 77 men and women (adults and older adults) with PD. The risk of sarcopenia was determined using the SARC-F and SARC-CalF screening tools. The diagnosis of sarcopenia was based on the new consensus published by the European Working Group on Sarcopenia in Older People (EWGSOP2). Sarcopenic obesity was diagnosed based on the criteria proposed by Stenholm. Disease stage and severity were determined using the Hoehn and Yahr scale and the Unified Parkinson Disease Rating Scale, respectively.

Results

The prevalence of sarcopenia was 19.5% and was associated with age, poor performance on activities of daily living and poor nutritional status. No significant association was found between the SARC-F score and the diagnosis of sarcopenia. The main factors that determined the variation in the parameters for the diagnosis of sarcopenia in the present sample were age, disease severity, body weight, and SARCF score.

Conclusion

Despite the low prevalence in the present study, sarcopenia progresses with the worsening of the nutritional status and functional capacity of individuals with PD. Further studies are needed on the factors involved in the genesis of sarcopenia. The SARC-F questionnaire is related to parameters for the diagnosis and severity of sarcopenia as well as the severity of PD.

Ray Dorsey E, Elbaz A, Nichols E, Abd-Allah F, Abdelalim A, Adsuar JC et al (2018) Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 17(11):939–953CrossRef

Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, Cooper C, Landi F, Rolland Y, Sayer AA, Schneider SM, Sieber CC, Topinkova E, Vandewoude M, Visser M, Zamboni M, Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2 (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48(4):601–601CrossRef

Drey M, Krieger B, Sieber CC, Bauer JM, Hettwer S, Bertsch T (2014) Motoneuron loss is associated with sarcopenia. J Am Med Dir Assoc [Internet]. 15(6):435–439. Available from: https://doi.org/10.1016/j.jamda.2014.02.002

Vetrano DL, Pisciotta MS, Laudisio A, Lo Monaco MR, Onder G, Brandi V et al (2018) Sarcopenia in Parkinson disease: comparison of different criteria and association with disease severity. J Am Med Dir Assoc [Internet] 19(6):523–527. Available from: https://doi.org/10.1016/j.jamda.2017.12.005CrossRef

Barichella M, Pinelli G, Iorio L, Cassani E, Valentino A, Pusani C, Ferri V, Bolliri C, Pasqua M, Pezzoli G, Frazzitta G, Cereda E (2016) Sarcopenia and dynapenia in patients with parkinsonism. J Am Med Dir Assoc [Internet]. 17(7):640–646. Available from: https://doi.org/10.1016/j.jamda.2016.03.016

Yazar T, Yazar HO, Zayimoğlu E, Çankaya S (2018) Incidence of sarcopenia and dynapenia according to stage in patients with idiopathic Parkinson’s disease. Neurol Sci 39(8):1415–1421CrossRef

Ozer FF, Akın S, Gultekin M, Zararsız GE (2019) Sarcopenia, dynapenia, and body composition in Parkinson’s disease: are they good predictors of disability?: a case–control study. Neurol Sci

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, Obeso J, Marek K, Litvan I, Lang AE, Halliday G, Goetz CG, Gasser T, Dubois B, Chan P, Bloem BR, Adler CH, Deuschl G (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1601CrossRef

Barbosa-Silva TG, Menezes AMB, Bielemann RM, Malmstrom TK, Gonzalez MC (2016) Enhancing SARC-F: Improving sarcopenia screening in the clinical practice. J Am Med Dir Assoc [Internet] 17(12):1136–1141. Available from: https://doi.org/10.1016/j.jamda.2016.08.004

10.

Stenholm S, Harris T, Rantenen T, Visser M, Kritchevsky SB, Ferrucci L (2008) Sarcopenic obesity-definition,etiology and consequences. Curr Opin Clin Nutr Metab Care 11(6):693–700CrossRef

11.

Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C, Sayer AA (2011) A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. Age Ageing 40(4):423–429CrossRef

12.

Sergi G, De Rui M, Veronese N, Bolzetta F, Berton L, Carraro S et al (2015) Assessing appendicular skeletal muscle mass with bioelectrical impedance analysis in free-living Caucasian older adults. Clin Nutr [Internet] 34(4):667–673. Available from: https://doi.org/10.1016/j.clnu.2014.07.010

13.

WHO. WHO_TRS_854.pdf [Internet]. 1995. p. 1–463. Available from: http://www.who.int/childgrowth/publications/physical_status/en/

14.

Organization WH. World Health Organization Obesity. Preventing and managing the global epidemic : report of a WHO Consultation. 1998. p. 275

15.

Barbosa-Silva TG, Bielemann RM, Gonzalez MC, Menezes AMB (2015) Prevalence of sarcopenia among community-dwelling elderly of a medium-sized South American city: results of the COMO VAI? Study J Cachexia Sarcopenia Muscle 7(2):136–143CrossRef

16.

Kyle UG , Genton L , Karsegard L , Slosman DO , Pichard C (2001) Single Prediction Equation for Bioelectrical Impedance Analysis in Adults Aged 20– 94 Years. Nutrition 17:248–253. https://doi.org/10.1016/s0899-9007(00)00553-0

17.

Hoehn MM, Yahr MD (1967) Parkinsonism : onset, progression, and mortality parkinsonism: onset, progression, and mortality. Neurol Int 17(5):427–442 Available from: http://www.neurology.org/content/17/5/427.citation

18.

Martínez-Martín P, Gil-Nagel A, Gracia LM, Gómez JB, Martínez-Sarriés J, Bermejo F (1994) Unified Parkinson’s disease rating scale characteristics and structure. Mov Disord 9(1):76–83CrossRef

19.

Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinková E, Vandewoude M, Zamboni M, European Working Group on Sarcopenia in Older People (2010) Sarcopenia: European consensus on definition and diagnosis. Age Ageing 39(4):412–423CrossRef

20.

Maetzler W, Drey M, Jacobs AH (2015) Sarkopenie und Frailty in der Neurologie. Nervenarzt. 86(4):420–430CrossRef

21.

Drey M, Hasmann SE, Krenovsky JP, Hobert MA, Straub S, Elshehabi M et al (2017) Associations between early markers of Parkinson’s disease and sarcopenia. Front Aging Neurosci 9(MAR):1–5

22.

Küsbeci ÖY (2019) Sarcopenia in Parkinson’s disease patients. 36(June 2015):28–32

23.

Alexandre TDS, Duarte YADO, Santos JLF, Wong R, Lebrão ML (2014) Prevalence and associated factors of sarcopenia among elderly in Brazil: findings from the sabe study. J Nutr Heal Aging. 18(3):284–290CrossRef

24.

Delmonico MJ, Harris TB, Visser M, Park SW, Conroy MB, Velasquez-Mieyer P, Boudreau R, Manini TM, Nevitt M, Newman AB, Goodpaster BH, Health, Aging, and Body (2009) Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr 90(6):1579–1585CrossRef

25.

Clark BC, Manini T (2012) What is dynapenia? Nutrition. 28(5):495–503CrossRef

26.

Kim M, Won CW (2019) Prevalence of sarcopenia in community-dwelling older adults using the definition of the European working group on sarcopenia in older people 2: findings from the Korean frailty and aging cohort study. Age Ageing 2:1–7

27.

Sayer AA, Syddall H, Martin H, Patel H, Baylis D, Cooper C (2008) The developmental origins of sarcopenia. J Nutr Heal Aging 12(7):427–432CrossRef

28.

Takata Y, Ansai T, Soh I, Awano S, Yoshitake Y, Kimura Y (2012) Physical fitness and 6.5-year mortality in an 85-year-old community-dwelling population. Arch Gerontol Geriatr [Internet] 54(1):28–33. Available from: https://doi.org/10.1016/j.archger.2011.04.014

29.

Lima LO, Scianni A, Rodrigues-de-Paula F (2013) Progressive resistance exercise improves strength and physical performance in people with mild to moderate Parkinson’s disease: a systematic review. J Physiother [Internet] 59(1):7–13. Available from: https://doi.org/10.1016/S1836-9553(13)70141-3

30.

Roberts HC, Syddall HE, Butchart JW, Stack EL, Cooper C, Sayer AA (2015) The association of grip strength with severity and duration of Parkinson’s: a cross-sectional study. Neurorehabil Neural Repair 29(9):889–896CrossRef

31.

Hubble RP, Silburn PA, Naughton GA, Cole MH (2016) Assessing stability in mild and moderate Parkinson’s disease: can clinical measures provide insight? Gait Posture [Internet] 49:7–13. Available from: https://doi.org/10.1016/j.gaitpost.2016.06.002

32.

Tan AH, Hew YC, Lim SY, Ramli NM, Kamaruzzaman SB, Tan MP et al (2018) Altered body composition, sarcopenia, frailty, and their clinico-biological correlates, in Parkinson’s disease. Park Relat Disord [Internet] 56(March):58–64. Available from. https://doi.org/10.1016/j.parkreldis.2018.06.020CrossRef

33.

Petroni ML, Albani G, Bicchiega V, Baudo S, Vinci C, Montesano A et al (2003) Body composition in advanced-stage Parkinson’s disease. Acta Diabetol 40(SUPPL. 1):187–190CrossRef

34.

Wang CK, Chen HL, Lu CH et al (2019) Altered body composition of psoas and thigh muscles in relation to frailty and severity of Parkinson’s disease. Int J Environ Res Public Health 16(19):3667. https://doi.org/10.3390/ijerph16193667

35.

Rolland Y, Dupuy C, Abellan Van Kan G, Cesari M, Vellas B, Faruch M et al (2017) Sarcopenia Screened by the SARC-F questionnaire and physical performances of elderly women: a cross-sectional study. J Am Med Dir Assoc [Internet] 18(10):848–852. Available from: https://doi.org/10.1016/j.jamda.2017.05.010

36.

Peball M, Mahlknecht P, Werkmann M, Marini K, Murr F, Herzmann H, Stockner H, de Marzi R, Heim B, Djamshidian A, Willeit P, Willeit J, Kiechl S, Valent D, Krismer F, Wenning GK, Nocker M, Mair K, Poewe W, Seppi K (2018) Prevalence and associated factors of sarcopenia and frailty in Parkinson’s disease: a cross-sectional study. Gerontology. 65(3):216–228CrossRef

37.

Allen NE, Canning CG, Sherrington C, Fung VSC (2009) Bradykinesia, muscle weakness and reduced muscle power in Parkinson’s disease. Mov Disord 24(9):1344–1351CrossRef

38.

Sirtori CR, Bolme PAD (1972) Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism. N Engl J Med 287(15):729–733CrossRef

39.

Kera T, Kawai H, Hirano H, Kojima M, Watanabe Y, Motokawa K et al (2020) Limitations of SARC-F in the diagnosis of sarcopenia in community-dwelling older adults. Arch Gerontol Geriatr [Internet] 87(July):103959. Available from: https://doi.org/10.1016/j.archger.2019.103959

Titel: Determinant factors of sarcopenia in individuals with Parkinson’s disease
verfasst von: Marcella Campos Lima da Luz
Gleyce Kelly Araújo Bezerra
Amdore Guescel C. Asano
Maria da Conceição Chaves de Lemos
Poliana Coelho Cabral
Publikationsdatum: 18.07.2020
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 3/2021
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-020-04601-4

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

23.04.2024 | Demenz | Nachrichten

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Determinant factors of sarcopenia in individuals with Parkinson’s disease

Abstract

Objective

Methods

Results

Conclusion

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2021

Clinical utility of the months backward test in patients with vascular cognitive impairment

Cryptococcal meningoencephalitis in a multiple sclerosis patient after fingolimod discontinuation—a case report

Takotsubo cardiomyopathy: an obscure cause of emerging cardiovascular manifestations in the setting of Bickerstaff’s brainstem encephalitis

Diagnostic usefulness of putaminal abnormality on diffusion- and susceptibility-weighted imaging: two illustrative cases of multiple system atrophy-parkinsonian type

Optic neuritis associated with sunitinib

Quality of life in neuro-Behçet’s disease: a cross-sectional study

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Neurologie